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Abstract  SA Fam Pract 2009;51(5):413-417
Background: Pharmacoepidemiological studies on ADHD are limited in South Africa. The primary aim was to analyse the prescribing of methylphenidate 
to patients aged 18 years and younger in the private health care sector.
Methods: Data for a one-month period in 2004 were obtained from a large medical aid administrator. Data were retrospectively analysed. The total 
database contained medicine records for 355 998 patients.
Results: A total of 66 450 medicine items were prescribed to 34 733 patients aged 18 years and younger. A total of 1 028 patients received 
prescriptions for methylphenidate. Nearly 3% of children and adolescents therefore received prescriptions for methylphenidate. The average age of 
these patients was 10.87 (SD = 2.79) years. Most of these prescriptions (63.14%) were for children between seven and twelve years of age. Most 
prescriptions were for long-acting methylphenidate in 20 mg, 30 mg and 40 mg capsules (48.87%). The average prescribed daily dose (PDD) for 
methylphenidate was 19.27 (SD = 11.87) mg. The most popular average PDD was 20 mg (42.63% of all methylphenidate prescriptions). The highest 
average percentage of methylphenidate prescriptions was in the Western Cape (2.58%), and the lowest in the Northern Cape (0.63%).
Conclusions: Numerous claims are being made that methylphenidate is overused or even abused, especially in children of school-going age. Most 
prescriptions were issued in metropolitan areas in this study, but overuse could not be established. This study was a preliminary study that can lead 
to more comprehensive studies in future.
  Peer reviewed. (Submitted:2008-11-13, Accepted:2009-02-06). © SAAFP 
Background to the study
Methylphenidate is the psychostimulant that is most frequently 
prescribed in the management of Attention Deficit/Hyperactivity Disorder 
(ADHD) and is also considered to be the first-line medication for the 
treatment of ADHD.1,2 ADHD is the most common neurodevelopmental 
disorder of childhood.1,3 ADHD also has the distinction of being both 
the most extensively studied childhood mental disorder and the most 
controversial.
Recently, the extensive use or overuse of stimulant medication has been 
a widely publicised concern1,4-7 and may be due, in part, to the lack of 
application of definitive diagnostic criteria and the non-specific nature of 
treatments.8 Marked increases in prescription rates of psychostimulants, 
especially methylphenidate, have also resulted in public health concerns 
about the frequency and appropriateness with which these medications 
are prescribed. The increase in prescription can partly be accounted for by 
the lengthening of the duration of treatment into adulthood, and increased 
treatment among girls. Epidemiologists have also stated that whether a 
child gets methylphenidate or an equivalent drug depends to a great deal 
on where he or she lives.9 The United States of America consumed 85% 
of Ritalin® (methylphenidate) produced in 1999, with striking variations 
between states and also between counties.10 Factors such as economic 
situation, geographic location and racial background have been shown 
to play a role in whether a child will receive methylphenidate or not.3,9,11
It is generally accepted that ADHD affects 3 to 5% of all school-aged 
children.2 Epidemiological data on ADHD and methylphenidate prescribing 
in South Africa is scarce. This study was an attempt to investigate 
the prescribing of methylphenidate in the nine provinces (different 
geographical regions) of South Africa using the claims database of one of 
the three largest medical aid scheme administrators in South Africa. The 
primary aim of the study was to analyse and compare the prescribing of 
methylphenidate to patients aged 18 years and younger in the private 
health care sector in South Africa.
Methodology
A retrospective, exposure cohort drug utilisation study was conducted. 
Data (computerised prescription records) for a one-month period in 
2004 were obtained from one of the three largest medical aid scheme 
administrators serving various private medical aid schemes in South 
Africa and were analysed. The total database contained medicine records 
for 355 998 patients who claimed one or more prescription items during 
the month. The medical aid administrator administers data for a variety 
of medical aids (including closed and open schemes), providing different 
packages to their members (saving schemes, over-the-counter medicine 
options and chronic programmes).
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All prescription records for methylphenidate were extracted from the 
database and analysed. Records contained information on the age of 
the patient, the date of the prescription, the province and the area of 
residence of the patient, detailed information on the dispensed drug 
(name, package size, formulation, strength and quantity) and price. The 
Monthly Index of Medical Specialities (MIMS)12 and the South African 
Medicines Formulary13 were used to classify drugs. All costs in the study 
are indicated in South African rand (R). One US dollar ($1.00) was equal 
to R6.21, one British pound (£1.00) was equal to R11.26, and one euro 
(€1.00) was equal to R7.57 on 30 June 2004. Ethical approval for the study 
was granted by the Faculty of Health Sciences Research, Technology and 
Innovation Committee of the Nelson Mandela Metropolitan University. 
The study adhered to ethical principles and patient confidentiality was 
maintained. No patient in the study could be identified or traced.
Limitations of the study were the absence of gender and clinical 
information in the database. Information about over-the-counter 
medication that patients used was also not included in the database and 
was therefore not analysed. Although the study may not necessarily be 
representative of prescription patterns in the entire private health care 
sector in South Africa, it does provide insight into the prescription of 
methylphenidate to patients of 18 years and younger, which can provide 
baseline information for more comprehensive studies in the future.
The focus of this study was only on the prescribing patterns of 
methylphenidate. It must be noted that a new non-stimulant product for 
ADHD, atomoxetine, has since been introduced onto the South African 
market. Generic equivalents for methylphenidate have also become 
available. These products were, however, not yet available on the market 
at the time of this study and could therefore not be included in the 
analysis.
Results and discussion
General prescribing patterns and demographic information of 
patient population
A total of 66 450 medicine items at a cost of R7 215 193 were prescribed 
to 34 733 patients aged 18 years and younger during the one-month 
period in 2004. The average cost per patient was R207.73 for the month, 
and the average cost per item was R108.58.
Nervous system drugs (under which methylphenidate is classified, 
Anatomical Therapeutic Chemical (ATC) classification N06BA0413,14 
accounted for 10.41% of the total number of medicine items and 
12.85% of the total cost of medicine prescribed to patients of 18 years 
and younger. Most medicine items (84.34%) were prescribed on an 
acute basis to these children (all therapeutic categories).
Nearly 3% (2.96%) of children and adolescents (18 years and younger) 
who had a prescription filled in the one-month period in 2004 had a 
prescription filled for at least one dose of a methylphenidate-containing 
product (1 028 patients of the 34 733 patients). A total of 1 028 patients 
of 18 years and younger were therefore prescribed methylphenidate. This 
proportional contribution of methylphenidate to all medicines prescribed 
for children and adolescents in this age group is one measure of utilisation, 
but is a poor measure of prevalence since it ignores the contribution 
to the denominator of very young children, in whom ADHD cannot be 
diagnosed. The age distribution, including prescribing frequency and 
cost, of all beneficiaries administered aged 18 years and younger who 
filled a prescription in the one-month period is given in Table I.
The average age of children and adolescents who received one or more 
methylphenidate-containing product was 10.87 (SD = 2.79) years. The 
youngest patient was 0.67 years, the oldest patient was 18.36 years, 
and the median age was 10.51 years. Most of the children (63.14%) 
were between seven and twelve years of age (see Table II). Of the total 
population of children and adolescents in the study, 27.04% (9 391 
of the 34 733 patients) were between seven and twelve years of age. 
This finding is in agreement with that of another South African study15 
conducted in Tshwane in which it was also found that primary school 
children (aged six to twelve years) received the highest percentage 
(61%) of methylphenidate prescriptions.
Prescribing frequency of methylphenidate
A total of 1 028 patients received 1 201 prescriptions for methylphenidate 
during the month. Two factors can be responsible for this finding. Firstly, 
not all patients received a full month’s supply of methylphenidate and 
it is possible that they may have received a second prescription for 
the month. Secondly, patients who go away on holiday often fill their 
prescriptions before the end of the month. In this case, two prescriptions 
will be claimed in the same month.
Table I: Age distribution of all beneficiaries aged 18 years and younger  
who filled a prescription in the one-month period
AGE (in years) NUMBER OF PATIENTS NUMBER OF ITEMS COST (in rand)
0 683 1 335 R116 701.98
1 3 056 6 167 R497 887.61
2 2 844 5 582 R481 328.11
3 3 172 6 146 R616 876.92
4 2 193 4 230 R384 539.08
5 1 961 3 783 R367 721.49
6 1 882 3 552 R341 973.31
7 1 665 3 069 R325 034.33
8 1 677 3 163 R357 913.52
9 1 557 2 897 R340 179.61
10 1 600 2 978 R365 669.13
11 1 431 2 731 R350 968.32
12 1 461 2 657 R338 941.60
13 1 441 2 733 R308 944.97
14 1 353 2 626 R320 923.86
15 1 547 3 052 R393 559.31
16 1 666 3 151 R407 663.71
17 1 757 3 274 R439 619.15
18 1 787 3 279 R458 747.18
TOTAL 34 733 66 450 R7 215 193.19
Table II: Age distribution of patients prescribed methylphenidate







TOTAL 1 028 100.00
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Methylphenidate is not indicated (not recommended) for children six 
years and younger.12,13 Specialist assessment prior to initiation is required, 
if possible.13 It was not possible in this study to determine whether 
methylphenidate was initiated by a general practitioner or a specialist. In 
this study, 4.86% of the patients who were prescribed methylphenidate 
(see Table II) were six years or younger. Most of these patients received 
prescriptions for methylphenidate 10 mg in a quantity of 30 tablets (that 
is, 10 mg methylphenidate per day). This is an indication of the off-label 
use of methylphenidate.
The specific trade names of methylphenidate that were prescribed are 
indicated in Table III. Ritalin® 10 mg tablets were the most frequently 
prescribed, followed by Ritalin LA® 20 mg capsules. The modified-
release (MR) forms of methylphenidate (Ritalin LA®) accounted for 
48.87% of total methylphenidate prescribing. According to the Scottish 
Health Statistics, MR forms of methylphenidate accounted for 54.9% of 
all methylphenidate prescribing in Scotland in 2006,16 which is roughly 
in agreement with the findings of this study. Another dosage form of 
methylphenidate (methylphenidate extended-release 18 mg, 36 mg 
and 54 mg capsules, Concerta®) has since been introduced onto the 
South African market.
Table IV illustrates the prescribing frequency of the different methyl-
phenidate dosage forms according to patient age.
More than 80% of methylphenidate prescriptions were for quantities of 
30 or 60 tablets or capsules (see Table V). Only 28.56% of methylphenidate 
prescriptions were, however, classified as chronic prescriptions.
As can be seen in Table VI, most methylphenidate prescriptions were 
for MR capsules (48.87%), followed by 10 mg tablets (39.97%) and 
sustained-release tablets (11.16%). Acute prescriptions are generally 
once-off prescriptions for a condition normally of an acute nature. 
It is also possible that a prescription is claimed as an acute prescription 
while awaiting approval (pre-certification) from the medical aid scheme 
to receive the medicine on a chronic basis. A chronic prescription is 
generally defined as a prescription for a period of at least three months 
for a potentially life-threatening condition that requires longer-term 
treatment. The terms “acute” and “chronic” were allocated by the 
medical aid administrator to the different prescriptions according to 
their standard classification system that they use for all the medical aid 
schemes that they administer. Prescribing differences were observed 
between the different trade names for acute and chronic prescriptions 
(χ2 = 6.23; d.f. = 2; p ≤ 0.05). There were more chronic prescriptions for 
Ritalin LA® capsules and more acute prescriptions for Ritalin® tablets.
Methylphenidate prescribing in the different provinces
Methylphenidate represented 1.81% (1 201 of 66 450 prescription 
items) of all prescriptions to children and adolescents, with the highest 
average percentages in the Western Cape (2.58%) followed by KwaZulu-
Natal (2.10%), and the lowest average percentages in the Northern Cape 
(0.63%) and Free State (1.16%). The percentage prescribing frequency 
of methylphenidate in the nine provinces is illustrated in Table VII.
From a more detailed analysis according to different areas (cities and 
towns in the provinces), it was evident that most prescriptions for 
methylphenidate were dispensed in cities (especially Johannesburg and 
Pretoria in Gauteng and Bellville in the Western Cape), as is illustrated 
in Table VIII. This is true if only prescription frequencies are considered. 
This was, however, not necessarily true when the number of patients 
Table III: Prescribing frequency of methylphenidate trade name products
TRADE NAME NUMBER PERCENTAGE (%)
Ritalin® 10 mg tablets 480 39.97
Ritalin LA® 20 mg capsules 465 38.72
Ritalin LA® 30 mg capsules 99 8.24
Ritalin LA® 40 mg capsules 23 1.91
Ritalin SR® 20 mg tablets 134 11.16
TOTAL 1 201 100.00
Table IV: Prescribing frequency of different methylphenidate dosage forms 
according to patient age
AGE (in years) Ritalin® Ritalin LA® Ritalin SR® TOTAL PERCENTAGE (%)
1 0 2 0 2 0.17
2 1 0 0 1 0.08
3 3 2 0 5 0.42
5 3 0 0 3 0.25
6 17 2 1 20 1.67
7 45 12 2 59 4.91
8 89 52 9 150 12.49
9 78 73 10 161 13.41
10 82 99 16 197 16.40
11 44 94 19 157 13.07
12 33 85 20 138 11.49
13 32 57 20 109 9.08
14 19 33 14 66 5.50
15 11 30 13 54 4.50
16 6 16 6 28 2.33
17 11 16 3 30 2.50
18 6 14 1 21 1.75
TOTAL 480 587 134 1 201 100.00
Table V: Quantities dispensed per dosage form of methylphenidate
QUANTITY 
(in tablets or 
capsules)
DOSAGE FORMS TOTAL
CAPSULES SUSTAINED-RELEASE TABLETS TABLETS NUMBER %
Less than 30 41 15 47 103 8.57
30 469 98 348 915 76.19
31–59 22 5 31 58 4.83
60 41 15 35 91 7.58
More than 60 14 1 19 34 2.83
TOTAL 587 134 480 1 201 100.00







(n = 343) NUMBER %
Ritalin® 42.19 34.40 480 39.97
Ritalin LA® 46.97 53.65 587 48.87
Ritalin SR® 10.84 11.95 134 11.16
TOTAL 100.00 100.00 1 201 100.00
* χ2 = 6.23; d.f. = 2; p ≤ 0.05.
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in each area was used as a denominator (as can be seen from the last 
column of Table VIII).
The percentage prescribing frequency and cost of methylphenidate is 
compared for the different provinces in Figure 1. The number of patients 
in each province aged 18 years and younger was as follows: Eastern 
Cape (2 232 patients), Free State (1 301 patients), Gauteng (16 989 
patients), KwaZulu-Natal (5 075 patients), Mpumalanga (1 723 patients), 
North-West Province (1 489 patients), Northern Cape (341 patients), 
Northern Province (664 patients) and Western Cape (4 919 patients), 
giving a total of 34 733 patients in the nine provinces.
The prescribing frequency of methylphenidate dosage types in the 
different provinces is illustrated in Figure 2. The average age of 
patients receiving methylphenidate was 10.87 (SD = 2.79; median = 
10.51) years. The average age of patients receiving Ritalin® was 9.97 
(SD = 2.78) years, Ritalin LA® 11.38 (SD = 2.66) years and Ritalin SR® 
11.97 (SD = 2.46) years. The immediate release products were 
therefore given, in general, to younger patients.
Dosages of methylphenidate prescribed
The Defined Daily Dose (DDD) for methylphenidate is 30 mg (oral).14 
The DDD corresponds to what is assumed to be the average dose 
per day for a drug, when it is used in its main indication in adults.17 
No DDD has been established for use in children, and since the 
focus of this study was on patients aged 18 years and younger, the 
average Prescribed Daily Dose (PDD) cannot be directly compared 
to the DDD. The DDD, however, remains a useful measurement 
unit for comparative purposes.
The average PDD for methylphenidate prescriptions in this study 
was 19.27 (SD = 11.87) mg, as can be seen in Table IX. The 
average PDD for acute methylphenidate prescriptions was 18.48 
(SD = 11.02) mg, and for chronic prescriptions 21.25 (SD = 13.60) 
mg. In this study, 20 mg was the most popular PDD (42.63% of 
prescriptions), followed by 10 mg (30.22% of prescriptions). This 
finding is different from a previous South African study18 where 
it was found that 10 mg was the most popular PDD (40.9% of 
prescriptions), followed by 20 mg (33.0% of prescriptions).
On average, only 8.74% of prescriptions for methylphenidate 
were prescribed in the DDD of 30 mg. Most of the prescriptions 
(82.93%) were in doses lower than the DDD. This pattern was 













Table VIII: Areas with the most methylphenidate prescriptions
RANK AREA






(n = 1 201) %
NUMBER  
(n = 66 405) %
1 Pretoria 10.02 12.54 129 10.74 7 646 1.69
2 Johannesburg North 10.61 9.33 123 10.24 5 270 2.33
3 Bellville 7.34 9.91 97 8.08 2 749 3.53





5.01 3.21 54 4.50 3 295 1.64
6 Durban 3.96 4.08 48 4.00 2 048 2.95
7 Port Elizabeth 4.43 2.92 48 4.00 1 628 2.95
8 Edenvale 4.20 2.33 44 3.66 2 413 1.82
9 Pietermaritzburg 2.68 5.54 42 3.50 1 109 3.79
10 Cape Town 3.15 3.79 40 3.33 2 025 1.98
11 Alberton 2.45 2.33 29 2.41 1 546 1.88
12 Kempton Park 2.45 2.04 28 2.33 1 946 1.44
13 Klerksdorp 1.98 1.75 23 1.92 972 2.37
14 Nelspruit 2.33 0.87 23 1.92 752 3.06
15 Stellenbosch 1.63 2.04 21 1.75 668 3.14
16 Benoni 1.40 2.33 20 1.67 1 266 1.58
17 Pinetown 1.17 2.92 20 1.67 804 2.49
18 Bloemfontein 1.98 0.58 19 1.58 1 308 1.45
19 East London 1.86 0.58 18 1.50 848 2.12
20 Bluff 1.75 0.29 16 1.33 507 3.16
Figure 1: Percentage prescription frequency and cost of methylphenidate
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consistent for all nine provinces (see Figure 3). This was to be expected, 
since the dose for children and adolescents should be lower than the 
adult dose (the DDD). This finding confirms that in clinical practice, 
methylphenidate dosages are related to body weight and age of the 
patient, and that a standard dose for all patients is not appropriate.
Conclusion and recommendations
ADHD has an impact on an individual’s psychological development, 
education and relationships, and also affects the family. It has been 
increasingly shown that ADHD often continues into adolescence and 
adulthood. These are aspects that warrant further research and could 
not be investigated in this study due to the limitations of prescription 
database studies.
Methylphenidate remains the mainstay in the treatment of ADHD. This 
study investigated methylphenidate prescribing and the population 
receiving these prescriptions. The results of this study were generally in 
agreement with those of previous South African studies. It was found that 
most methylphenidate prescriptions (63.14%) were issued to children 
between seven and twelve years of age, most prescriptions were for 
30 tablets or capsules, and the average PDD for methylphenidate was 
19.27 mg. Numerous claims are being made that methylphenidate is 
overused or even abused, especially in children of school-going age. 
Most prescriptions, based on frequency, were issued in metropolitan 
areas (cities) in this study, but overuse could not be established.
Not many studies have been published that investigate drug utilisation 
or prescribing differences between the nine provinces in South Africa 
and no similar study could be found for methylphenidate. This study has 
limitations, in that it was a cross-sectional study, the study only covered 
a small percentage of the private health care sector in South Africa and 
the recent introduction of more and newer products for ADHD were not 
covered in this study. This study must therefore be seen as a preliminary 
study to provide some baseline information of methylphenidate 
prescribing for ADHD in the different provinces of South Africa that can 
lead to more comprehensive studies in future.
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Table IX: Average PDDs for chronic and acute methylphenidate 
prescriptions per province
PROVINCE AVERAGE AGE (in years)
AVERAGE PDD (in mg)
ACUTE CHRONIC TOTAL
Eastern Cape 10.57 16.83 21.67 17.77
Free State 11.29 20.24 26.53 21.45
Gauteng 10.68 18.41 21.00 19.15
KwaZulu-Natal 11.51 17.03 23.23 19.01
Mpumalanga 10.88 19.45 22.08 20.08
North-West Province 10.18 19.13 22.14 20.27
Northern Cape 9.23 23.33 - 23.33
Northern Province 11.21 20.42 13.33 19.00
Western Cape 10.98 19.80 19.27 19.64
ALL PROVINCES 10.87 18.48 21.25 19.27
